BELLEVUE, WA / ACCESS Newswire / June 3, 2026 / Dear Fellow Shareholders,
As we move through 2026, I would like to provide an update on where OSR Holdings (NASDAQ:OSRH) stands today and how we are approaching the opportunities ahead:
Strategic Focus and Business Development
Over the past year, we have continued to strengthen our position as a biomedical holding company with a growing portfolio of innovative businesses spanning oncology, regenerative medicine, medical devices, and digital health. We are seeing increasing external validation of the technologies and platforms being developed by our subsidiaries.
Vaximm recently executed a definitive licensing agreement for the VXM01 immunotherapy platform, one of the most significant transactions in the Company's history. At Woori IO, development activities and strategic engagements involving global industry participants, including Samsung, continue to advance our noninvasive glucose monitoring platform.
